2026-09-16T14:54:45-04:00 2025-12-31 372123844 CASCADE CPA 421 WATER STREET 111 PRAIRIE DU SAC WI 53578 990 2025-01-01 871500208 WISCONSIN INSTITUTE FOR IMMUNE AND CELL THERAPY INC WISC 6087291450 726 POST ROAD MADISON WI 537134620 GARY A DAHL PRESIDENT 6087291450 2026-09-03 true JULIE MILLER P00388780 6086440206 2026-09-03 2025 WIICT GARY A DAHL 726 POST ROAD MADISON WI 53713 633111 false X X 2021 WI THE ORGANIZATION'S PRIMARY EXEMPT PURPOSE IS TO ENGAGE IN THE CONTINUOUS ACTIVE CONDUCT OF MEDICAL RESEARCH IN CONJUNCTION WITH A HOSPITAL. 3 3 3 3 0 2027000 573009 13755 1986 9617 58116 0 2050372 633111 0 0 341677 307482 0 0 63277 53520 404954 361002 1645418 272109 1823568 2083502 15310 3135 1808258 2080367 X THE ORGANIZATION'S PRIMARY EXEMPT PURPOSE IS TO ENGAGE IN THE CONTINUOUS ACTIVE CONDUCT OF MEDICAL RESEARCH IN CONJUNCTION WITH A HOSPITAL. false false 316907 1986 IN 2025, WIICT WORKED AS A COLLABORATOR WITH RESEARCHERS AND CLINICIANS FROM INSTITUTIONS INCLUDING: ST. JUDE'S CHILDREN'S HOSPITAL, NATIONAL INSTITUTE FOR ALLERGY AND INFECTIOUS DISEASE/NATIONAL INSTITUTES OF HEALTH, MASSACHUSETTS GENERAL HOSPITAL AND MASSACHUSETTS GENERAL BRIGHAM. COLLABORATIONS INCLUDED THE PRODUCTION OF RESEARCH-GRADE MRNAS FOR USE IN THE DISCOVERY PROCESS FOR BOTH GENE REPLACEMENT AND GENOME-EDITING-BASED THERAPEUTIC TREATMENTS AS WELL AS ONGOING RESEARCH INTO FUTURE ITERATIONS (NEXT GENERATION) FORMS OF THESE TREATMENTS. WIICT ALSO PRODUCED GMP-GRADE MRNAS FOR USE IN BOTH GENE REPLACEMENT AND GENOME-EDITING-BASED THERAPEUTIC TREATMENTS IN FDA-SANCTIONED CLINICAL TRIALS. ONE EXAMPLE IS THE SUCCESSFUL TREATMENT OF THE FIRST EVER IN HUMAN GENE THERAPY TO TREAT AND CURE X-LINKED HYPER IGM SYNDROME (CD40 LIGAND DEFICIENCY), A SERIOUS IMMUNODEFICIENCY DISEASE. 316907 true true false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false true false false false true 1 0 3 true false false false false false false false false false false false false false false X 3 3 true false false false false false false true true false false true true true true false false false false false X GARY A DAHL 6087291450 726 POST ROAD MADISON WI 53713 X GARY A DAHL PRESIDENT 1.00 X X 0 0 0 JEROME J JENDRISAK VP, SEC/TREA 1.00 X X 0 0 0 KIERAN COE DIRECTOR 0.10 X 0 0 0 false false false 573009 573009 RESEARCH SERVICES AT COST 900999 1986 1986 1986 58116 58116 633111 1986 58116 260058 260058 27336 27336 20088 20088 1680 1680 13403 9126 4277 2720 2720 OTHER CONSULTING SERVICES 35223 35223 BIOLOGICALS & CHEM R&D 299 299 BANK CHARGES 160 160 LICENSES & FEES 25 25 10 10 361002 316907 44095 0 52847 41305 1769786 2041505 935 692 1823568 2083502 15310 3135 15310 3135 X 65000 65000 1743258 2015367 1808258 2080367 1823568 2083502 272109 X false false false X NATIONAL INSTITUTES OF HEALTH CLINICAL CENTER BETHESDA MD RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED FORM 990, PAGE 2, PART III, LINE 4A IN 2025, WIICT WORKED AS A COLLABORATOR WITH RESEARCHERS AND CLINICIANS FROM INSTITUTIONS INCLUDING: ST. JUDE'S CHILDREN'S HOSPITAL, NATIONAL INSTITUTE FOR ALLERGY AND INFECTIOUS DISEASE/NATIONAL INSTITUTES OF HEALTH, MASSACHUSETTS GENERAL HOSPITAL AND MASSACHUSETTS GENERAL BRIGHAM. COLLABORATIONS INCLUDED THE PRODUCTION OF RESEARCH-GRADE MRNAS FOR USE IN THE DISCOVERY PROCESS FOR BOTH GENE REPLACEMENT AND GENOME-EDITING-BASED THERAPEUTIC TREATMENTS AS WELL AS ONGOING RESEARCH INTO FUTURE ITERATIONS (NEXT GENERATION) FORMS OF THESE TREATMENTS. WIICT ALSO PRODUCED GMP-GRADE MRNAS FOR USE IN BOTH GENE REPLACEMENT AND GENOME-EDITING-BASED THERAPEUTIC TREATMENTS IN FDA-SANCTIONED CLINICAL TRIALS. ONE EXAMPLE IS THE SUCCESSFUL TREATMENT OF THE FIRST EVER IN HUMAN GENE THERAPY TO TREAT AND CURE X-LINKED HYPER IGM SYNDROME (CD40 LIGAND DEFICIENCY), A SERIOUS IMMUNODEFICIENCY DISEASE. FORM 990, PAGE 6, PART VI, LINE 2 JERRY JENDRISAK GARY DAHL JOINTLY OWN OTHER BUSINESSES FORM 990, PAGE 6, PART VI, LINE 11B A COPY OF THE FORM 990 IS PROVIDED TO THE GOVERNING BODY PRIOR TO BEING FILED WITH THE INTERNAL REVENUE SERVICE FORM 990, PAGE 6, PART VI, LINE 12C THE ORGANIZATIONS WRITTEN CONFLICT OF INTEREST POLICY COVERS ANY "INTERESTED PERSON" COMPRISED OF ALL DIRECTORS OF THE BOARD OF DIRECTORS, OFFICERS, MEMBERS OF A COMMITTEE, OR STAFF MEMBERS OF THE ORGANIZATION. EVERY INTERESTED PERSON HAS A DUTY TO DISCLOSE POTENTIAL OR ACTUAL CONFLICT OF INTEREST EXISTS OCCUR AT ANY LEVEL WHERE THE PERSONAL, PROFESSIONAL, FINANCIAL INTEREST, OR FIDUCIARY DUTY OF THE INTERESTED PERSON IS OPPOSED TO THE ORGANIZATION, CONFLICTS WITH, OR INFLUENCES THE INTERESTED PERSON'S ACTIONS AND JUDGEMENT. THE BOARD OF DIRECTORS OR AN APPLICABLE COMMITTEE DESIGNATED BY THE BOARD WILL REVIEW AND DETERMINE WHETHER A POTENTIAL OR ACTUAL CONFLICT OF INTEREST EXISTS WITH RESPECT TO EACH INTERESTED PERSON. THE INTERESTED PERSONS IN WHICH A CONFLICT OF INTEREST EXISTS WILL BE PROHIBITED FROM PARTICIPATING IN THE DELIBERATIONS UNLESS TO ANSWER QUETIONS, AND WILL NEVER BE PRESENT WHEN DECISIONS ON CONFLICT RELATED TO A TRANSACTION ARE MADE. FORM 990, PAGE 6, PART VI, LINE 19 THE ORGANIZATION DOES NOT MAKE ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC. WISCOTX HOLDINGS LLC 726 POST ROAD MADISON WI 53713 465122681 HOLDING CO WI N/A false false CELLSCRIPT LLC 726 POST ROAD MADISON WI 53713 463213828 MANUFACTUR WI N/A C CORP false false false true false false false false false false false false false false true false true true false false WISCOTX HOLDINGS LLC C 572000 CASH DONATION CELLSCRIPT LLC N COST/ALLOCATION AGREEMENT CELLSCRIPT LLC P 35222 COST/ALLOCATION AGREEMENT CELLSCRIPT LLC Q 1986 COST/ALLOCATION AGREEMENT SCHEDULE R PART V (2) CELLSCRIPT, LLC PROVIDES WISCONSIN INSTITUTE FOR IMMUNE AND CELL THERAPY, INC THE USE OF PORTIONS OF THEIR FACITLITY AT NO COST. PART III-1 WISCOTX HOLDINGS LLC EIN - 46-5122681 PART III (D) WISCOTX HOLDINGS LLC WIICT IS NOT AN OWNER OF WISCOTX HOLDINGS, LLC OR CELLSCRIPT, LLC AND THEREFORE HAS NO SHARE OF INCOME, ASSETS, OR PERENTAGE OWNERSHIP.